Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cells
Asıl Yazarlar: Wen, Wei, Marcinkowski, Emily, Luyimbazi, David, Luu, Thehang, Xing, Quanhua, Yan, Jin, Wang, Yujun, Wu, Jun, Guo, Yuming, Tully, Dylan, Han, Ernest S., Yost, Susan E., Yuan, Yuan, Yim, John H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770784/
https://ncbi.nlm.nih.gov/pubmed/31480338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8091010
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller